Novel Amino-pyridine Derivatives Field of the invention The present invention relates to S1P1/EDG1 receptor agonists of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing a compound of the formula (I), and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies. Background of the invention The human immune system is designed to defend the body against foreign micro¬organisms and substances that cause infection or disease. Complex regulatory mechanisms ensure that the immune response is targeted against the intruding substance or organism and not against the host, in some cases, these control mechanisms are unregulated and autoimmune responses can develop. A consequence of the uncontrolled inflammatory response is severe organ, cell, tissue or joint damage. With current treatment, the whole immune system is usually suppressed and the body's ability to react to infections is also severely compromised. Typical drugs in this class include azathioprine, chlorambucil, cyclophosphamide, cyclosporin, or methotrexate. Corticosteroids which reduce inflammation and suppress the immune response, may cause side effects when used in long term treatment. Nonsteroidal anti-infammatory drugs (NSAIDs) can reduce pain and inflammation, however, they exhibit considerable side effects. Alternative treatments include agents that activate or block cytokine signaling. Orally active compounds with immunomodulating properties, without compromising immune responses and with reduced side effects would significantly improve current treatments of uncontrolled inflammatory disease. In the field of organ transplantation the host immune response must be suppressed to prevent organ rejection. Organ transplant recipients can experience some rejection even when they are taking immunosuppressive drugs. Rejection occurs most frequently in the first few weeks after transplantation, but rejection episodes can also happen months or even years after transplantation. Combinations of up to three or four medications are commonly used to give maximum protection against rejection while minimizing side effects. Current standard drugs used to treat the rejection of transplanted organs interfere with discrete intracellular pathways in the activation of T-type or B-type white blood cells. Examples of such drugs are cyclosporin, daclizumab, basiliximab, everolimus, or FK506, which interfere with cytokine release or signaling; azathioprine or leflunomide, which inhibit nucleotide synthesis; or 15-deoxyspergualin, an inhibitor of leukocyte differentiation. The beneficial effects of broad immunosuppressive therapies relate to their effects; however, the generalized immunosuppression which these drugs produce diminishes the immune system's defense against infection and malignancies. Furthermore, standard immunosuppressive drugs are often used at high dosages and can cause or accelerate organ damage. Description of the invention The present invention provides novel compounds of formula (I) that are agonists for the G protein-coupled receptor S1P1/EDG1 and have a powerful and long-lasting immunomodulating effect which is achieved by reducing the number of circulating and infiltrating T- and B-lymphocytes, without affecting their maturation, memory, or expansion. The reduction of circulating T- / B-lymphocytes as a result of S1P1/EDG1 agonism, possibly in combination with the observed improvement of endothelial cell layer function associated with S1P1/EDG1 activation, makes such compounds useful to treat uncontrolled inflammatory disease and to improve vascular functionality. The compounds of the present invention can be utilized alone or in combination with standard drugs inhibiting T-cell activation, to provide a new immunomodulating therapy with a reduced propensity for infections when compared to standard immunosuppressive therapy. Furthermore, the compounds of the present invention can be used in combination with reduced dosages of traditional immunosuppressant therapies, to provide on the one hand effective immunomodulating activity, while on the other hand reducing end organ damage associated with higher doses of standard immunosuppressive drugs. The observation of improved endothelial cell layer function associated with S1P1/EDG1 activation provides additional benefits of compounds to improve vascular function. The nucleotide sequence and the amino acid sequence for the human S1P1/EDG1 receptor are known in the art and are published in e.g.: HIa, T., and Maciag, T. J. Biol Chem. 265 (1990), 9308-9313; WO 91/15583 published 17 October 1991; WO 99/46277 published 16 September 1999. The potency and efficacy of the compounds of formula (I) are assessed using a GTPyS assay to determine EC50 values and by measuring the circulating lymphocytes in the rat after oral administration, respectively (see in Examples). wherein the asterisks indicate the bond that is linked to the pyridine group of formula (I); R1 represents hydrogen, or C1-3-aikyI; R2 represents C1-4-alkyl or R1 and R2, together with the nitrogen atom to which they are attached, form a pyrrolidine, piperidine, or morpholine ring, such as especially a pyrrolidine ring; R^ represents C1-4-alkyl, or chloro; R" represents hydrogen, C1-4-alkyl, C1-5-alkoxy, or halogen; R^ represents hydrogen,C1-4-alkyl, C1-3-alkoxy, or halogen; R® represents hydrogen, hydroxy-C.g-alkyl, 2,3-dihydroxypropyl, di-(hydroxy-C1-4-alkyl)-Ci. 4-alkyl, -CH2-(CH2)k-NR®'R'', -CH2-(CH2)rNHS02R'', -(CH2)nCH(OH)-CH2-NHS02R'^ -CH2-(CH2)k-NHCOR'\ -(CH2)nCH(OH)-CH2-NHCOR'\ -CH2-{CH2)n-CONR'''R^^ -CO-NHR'^^ , 1 -(3-carboxy-azetidinyl)-2-acetyi, 1 -(2-carboxy-pyrrolidinyl)-2-acetyl, 1 -(3-carboxy-pyrrolidinyl)-2-acetyl, 1 -(3-carboxy-azetidinyl)-3-propionyl, 1 -(2-carboxy-pyrrolidinyl)-3-propionyl, 1-(3-carboxy-pyrrolidinyl)-3-propionyl, -(CH2)nCH(OH)-CH2-NR®^R^^ hydroxy, C1-4 -alkoxy, hydroxy-Ca-g-alkoxy, di-(hydroxy-C1-4-alkyl)-C1-4-alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-methoxy-propoxy, -OCH2-{CH2)m-NR'^^R^^, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(azetidine-3-carboxylic acid C1-5-alkylester)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid C1-5-alkylester)-1-yl]-ethoxy, -OCH2-CH(OH)-CH2-NR^'R^^ 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxypropoxy, 3-[(azetidine-3-carboxylic acid C1-5-alkylester)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid C1-5 5-alkylester)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid C1-5-alkylester)-1-yl]-propoxy, -OCH2-(CH2)m-NHS02R^^ -OCH2-CH(OH)-CH2-NHS02R", -OCH2-(CH2)m-NHCOR^\ -0CH2-CH(0H)-CH2-NHCOR'*, -NR'^R^', -NHCO-R'\or -SO2NHR"; R®' represents hydrogen, C1-4alkyI, 2-hydroxyethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2,3-dihydroxypropyl, carboxymethyl, {C1-5-alkylcarboxy)methyl, 2-carboxyethyl, 2-(Ci.5-alkylcarboxy)ethyl, or 2-aminoethyl; R®^ represents hydrogen, methyl, or ethyl; R*^ represents C1-3-alkyI, methylamino, ethylamino, or dimethylamlno; R®" represents hydroxy-C1-2-alkyl, or R^^R^^N-Cis-alkyl; R®' and R" independently represent hydrogen, or methyl; k represents the integer 1, 2, or 3; 5 m represents the integer 1 or 2; n represents 0, 1, or 2; and R7 represents hydrogen, Ci.4-all2,4]oxadia20l-3-yl]-phenol The title compound is obtained (122 mg) in analogy to Example 5 starting from 2-chloro-4,N-dihydroxy-benzamidine (800 mg, 4.29 mmol) and 2-(diethylamino)-6-methyl-isonicotinic acid (1.13 g, 4.29 mmol); LC-MS: IR = 0.82 min; [M+1]" = 359.04. Example 123 (S)-3-{3-Chloro-4-[5-(2-diethylamino-6-methyl-pyridln-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol The title compound is prepared from Example 122 in analogy to Example 4; LC-MS: IR -0,75 min; [M+1]^ = 427.13; 'H NMR (CDCI3): ^1.24 (t, J = 7.0 Hz, 6 H), 2.03 (s br, 1 H), 2.49 (s, 3 H), 2.62 (s br, 1 H), 3.62 (q, J = 7.0 Hz, 4 H), 3.77-3.84 (m, 1 H), 3.86-3.93 (m, 1 H), 4.12-4.22 (m, 3 H), 6.96-7.02 (m, 2 H), 7.09 (s, 1 H), 7.14 (s, 1 H), 8.01 (d, J = 8.8 Hz, 1 H). Example 124 rac-3-{4-[5-(2-Diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-3-methyl-phenoxy}-propane-1,2-diol The title compound is prepared in analogy to Example 1 starting fronn 2-(diethylamino)-6-methyl-isonicotinic acid and 4-allyloxy-N-hydroxy-2-methyl-ben2amidine; LC-MS: in = 0.75 min; [M+1]' =413.26; 'H NMR (CD3OD): (U.24 (t, J = 7.0 Hz, 6 H), 2.46 (s, 3 H), 2,64 (s, 3 H), 3.64 (q, J = 7.0 Hz, 4 H), 3.67-3.77 (m, 2 H), 3.99-4.09 (m, 2 H), 4.16 (dd, J = 9.5, 4.3 Hz, 1 H), 6.95-7.00 (m, 2 H), 7.06 (d, J = 3.3 Hz, 2 H), 8.02 (d, J = 8.5 Hz, 1 H). Example 125 rac-N-(3-{4-[5-(2-Diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-3-methyl- phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide The title compound is prepared in analogy to Example 32 starting from Example 124; LC-MS: tR = 0.73 min; [M+1]^ = 470.27; ^H NMR (CD3OD): ^1.23 (t, J = 7.0 Hz, 6 H), 2.45 (s, 3 H), 2.64 (s, 3 H), 3.44 (dd, J = 13.8, 6.5 Hz, 1 H), 3.58-3.67 (m, 5 H), 4.04 (s, 2 H), 4.05-4.15 (m, 3 H), 6.94-6.99 (m, 2 H), 7.04 (d, J = 2.8 Hz, 2 H), 8.01 (d, J = 8.3 Hz, 1 H). Example 127 'H NMR (CDCI3); J1.22(d, J = 6.5Hz, 6H), 1.29 (t, J = 7.5 Hz, 3 H), 2.35 (s, 2 H), 2.48 (s, 3 H), 2.72 (q, J = 7.5 Hz, 2 H), 2.94 (S, 3 H), 3.14-3.33 (m, 2 H), 3.84-3.92 (m, 3 H), 3.99 (s br, 2 H), 4.25-4.35 (m, 1 H), 4.97 (hept, J = 6.5 Hz), 5.58 (s br, 1 H), 7.00 (s, 1 H), 7.06 (s, 1 H),7.79(s, 1 H),7.82(s, 1 H), Example 130 'H NMR (CDCI3): ^^1.24 (d, J = 6.8 Hz, 6 H), 1.32 (t, J = 7.5 Hz, 3 H), 2.39 (s, 3 H), 2,51 (s, 3 H), 2.75 (q, J = 7.5 Hz, 2 H), 2,93 (s br, 1 H), 2.97 (s, 3 H), 3.45-3.57 (m, 2 H), 3.76-3,93 (m, 3 H), 4.17-4.24 (m, 3 H), 4.93-5.06 (m, 1 H), 7.05 (s, 1 H), 7.08 (t br, ^ = 5.3 Hz, 1 H), 7.12 (s, 1 H), 7.87 (s, 1 H), 7.88 (s, 1 H). Examples 131 to 132 The following Examples are prepared in analogy to previous Examples starting from 2-(isopropyl-methyl-amino)-6-methyl-isonicotinic acid and 4,N-dihydroxy-3-methyl-5-propyl-benzamidine. Example 133 'H NMR (Dg-DMSO): -ethylamino)-acetic acid ethyl ester The title compound is prepared from Example 246 in analogy to Example 55 by reacting the mesylate intermediate with glycine ethyl ester rather than sodium azide; LC-MS: IR = 0.69 min; [M+1]" = 438.20. Example 252 (2-{4-[5-(2-Diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethylamino)-acetic acid The title compound is obtained as a hydrochloride salt upon treating Example 251 with 4 N HCI in dioxane; LC-MS: tn = 0,67* min; [M+1]' = 410.11; 'H NMR (D2O): S 1.26 (t, J = 7.0 ■4 r\ri Hz, 6 H), 2.53 (s, 3 H), 3.12 (t, J = 7.5 Hz, 2 H), 3.40 (t, J = 7.3 Hz, 2 H), 3.67 (q, J = 7.0 Hz, 4 H), 3.78 (s, 2 H), 7.18 (s, 1 H), 7.50 (d, J = 7.8 Hz, 2 H), 7.58 (s, 1 H), 8.01 (d, J = 7.5 Hz, 2 H). Example 253 Diethyl-{6-methyl-4-[3-(4-propoxy-phenyl)-[1,2,4]oxacliazol-5-yl]-pyridin-2-yl}-amine The title compound is prepared in analogy to Example 5 starting from N-hydroxy-4-propoxy-benzamidine and 2-diethylamino-6-methyl-isQnicotinic acid; LC-MS: tp = 1.41* min; [M+1]" = 367.09. Example 254 {4-[v3-(2,3-Dimethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-6-methyl-pyriclin-2-yl}-diethyl- amine The title compound is prepared in analogy to Example 5 starting from N-hydroxy-2,3-dimethoxy-benzamidine and 2-diethylamino-6-methyl-isonicotinic acid; LC-MS: tp = 1.16* min; [M+1]" - 369.03. Example 255 (Reference Example) rac-1-{4-[5-(2-Diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}- ethane-1,2-diol The title compound is prepared in analogy to Example 1 starting from N-hydroxy-4-vinyl-benzamidine and 2-diethylamino-6-methyl-isonicotinic acid; LC-MS: tR = 0.69 min, [M+1]* = 369.11. Example 256 rac-1-{4-[5-(2-Diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-2-(2- hydroxy-ethylamino)~ethanol Example 255 is transformed into the corresponding mesylate and then reacted with ethanolamine in analogy to the procedures given in Example 55 to give the title compound; tH = 0.61 min, [M+1]* =412.18. Example 257 rac-N-(2-{4-[5-(2-Diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-2- hydroxy-ethyl)-methanesulfonamide Example 255 is transformed into the corresponding mesylate and then reacted with methane sulfonamide potassium salt in analogy to the procedures given in Example 55 to ■ give the title compound; tR = 0.73 min, [M+1]' = 446.14. Example 258 N-{4-[5-{2-Diethylammo-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-phenyl}- acetamide The title compound is prepared in analogy to Example 5 starting from N-[2-ethyl-4-(N-hydroxycarbamimidoyl)-phenyl]-acetamide and 2-diethylamino-6-methyl-isonicotinic acid; LC-MS: tR - 0.81 min, [M+1]" =: 394.15;'H NMR (CDCI3): dM .25 (t, J = 7.0 Hz, 6 H), 1.36 (t, J = 7.3 Hz, 3 H), 2.28 (s, 3 H), 2.50 (s, 3 H), 2.73 (q, J = 7,3 Hz, 2 H), 3.63 (q, J = 6.8 Hz, 4 H), 7.01 (s, 1 H), 7.08-7.16 (m, 2 H), 8.03-8.09 (m, 2 H), 8.13-8.21 (m, 1 H). Example 259: GTPYS assay to determine EC^ values GTPyS binding assays are performed in 96 well microliter plates (Nunc, 442587) in a final volume of 200 pi, using membrane preparations of CHO cells expressing recombinant human SI PI receptor. Assay conditions are 20 mM Hepes (Fluka, 54461), 100 mM NaCI (Fluka, 71378), 5 mM MgCb (Fluka, 63064), 0.1% BSA (Calbiochem, 126609), 1 pM GDP (Sigma, G-7127), 2.5% DMSO (Fluka, 41644), 50 pM ^^S-GTPyS (Amersham Biosciences, SJ1320), The pH is 7.4. Test compounds are dissolved and diluted in 100% DMSO and pre-incubated at room temperature for 30 min in 150 pi of the above assay buffer, in the absence of ^^S-GTPyS. After addition of 50 pi of ^^S-GTPyS, the assay is incubated for 1 h at rt. The assay is terminated by transfer of the reaction mixture to a Multiscreen plate (Millipore, MAHFCIH60) using a cell harvester from Packard Biosciences, and the plates are washed with ice-cold 10 mM NaaHPO^/NaHaPO^ (70%/30%), dried, sealed at the bottom and, after addition of 25 pi MicroScint20 (Packard Biosciences, order# 6013621), sealed on the top. Membrane-bound ^^S-GTPyS is measured with a TopCount from Packard Biosciences. EC50 is the concentration of agonist inducing 50 % of the maximal specific ^^S-GTPyS binding. Specific binding is determined by subtracting non-specific binding from maximal binding. Maximal binding is the amount of cpm bound to the Multiscreen plate in the presence of 10 pM of S1P. Non-specific binding is the amount of binding in the absence of an agonist in the assay. Agonistic activities (EC50 values) of 206 from 258 exemplified compounds have been measured (the compounds of Examples 16, 18, 35, 36, 39, 48, 74, 81, 84, 85, 88, 91, 92, 96, 99, 100, 106, 107, 119, 122, 136, 137, 143, 144, 154, 161, 168, 171, 172, 175, 182, 185, 186, 191, 195, 197, 200, 201, 205, 222, 223, 229, 230, and 234 have not been nneasured). The compounds of Examples 34, 90, 176, 178, 179, 208 and 209 showed ECso values of greater than 10 |aM. All the other measured compounds exhibit ECBO values in the range of 0.1 to 9180 nM with an average of 344 nM. Agonistic activities of some compounds of formula (I) are displayed in Table 1. Example 260: Assessment of In vivo Efficacy The efficacy of the compounds of formula (I) is assessed by measuring the circulating lymphocytes after oral administration of 3 to 30 mg/kg of a compound of formula (I) to normotensive male Wistar rats. The animals are housed in climate-controlled conditions with a 12 h-light/dark cycle, and have free access to normal rat chow and drinking water. Blood is collected before and 3, 6 and 24 h after drug administration. Full blood is subjected to hematology using Advia Hematology system (Bayer Diagnostics, Zurich, Switzerland). All data are presented as mean ± SEM. Statistical analyses are performed by analysis of variance (ANOVA) using Statistica (StatSoft) and the Student-Newman-Keuls procedure for multiple comparisons. The null hypothesis is rejected when p < 0.05. As an example, Table 2 shows the effect on lymphocyte counts 6 h after oral administration of 10 mg/kg of some compounds of formula (I) to normotensive male Wistar rats as compared to a group of animals treated with vehicle only. Lymphocyte counts 6 h after oral administration have been measured for 39 of the 258 exemplified compounds and are in the range of -82 % to -48 % with an average of -65 %. wherein the asterisks indicate the bond that is linked to the pyridine group of formula (I); R1 represents hydrogen, or C1-3-alkyl; R2 represents C1-4 -alkyl; or R1 and R2, together with the nitrogen atom to which they are attaclied, fornn a pyrrolidine, piperidine, or nncrpholine ring; R3 represents C1-4 -alkyl, or chloro; R4 represents hydrogen,C1-4 -alkyl, C1-3-alkoxy, or halogen; R5 represents hydrogen, C1-4 -alkyl, C1-3-alkoxy, or halogen; R6 represents hydrogen, hydroxy-C1-5-alkyl, 2,3-dihydroxypropyl, di-(hydroxy-C1-4 -alkyl)-Ci. 4-alkyl, -CH2-(CH2),-NR<''R''', -CH2-(CH2)k-NHSO^R'^^ -(CH2)nCH(OH)-CH2-NHS02R'', -CH2-(CH2)k-NHCOR'^\ -(CH2)nCH(OH)-CH2-NHCOR'', -CH2-(CH^)n-C0NR'^'R''^ -CO-NHR'^\ 1-(3-carboxy-azetidinyi)-2-acetyl, 1-(2-carboxy-pyrrolid(nyl)-2-acetyl, 1-(3-carboxy-pyrrolidinyl)-2-acetyl, 1 -(3-carboxy-azetidinyl)-3-propionyl, 1 -(2-carboxy-pyrrolidinyl)-3-propionyl, 1-(3-carboxy-pyrrolidinyl)-3-propionyl, -(CH2)nCH(OH)-CH2-NR'^'R^^ hydroxy, C1-4 4-alkoxy, hydroxy-C2.5-alkoxy, di-(hydroxy-C1-4 -alkyl)-C1-4 -alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-methoxy-propoxy, -OCH2-(CH2)m-NR^'R°^, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(a2etidine-3-carboxylic acid C1-5-alkylester)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxy!ic acid C1-5-alkylester)-1-yl]-ethoxy, -OCH2-CH(OH)-CH2-NR'^^R'^^ 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxypropoxy, 3-[(azetidine-3-carboxylic acid C1-5-alkylester)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid C1-5 5-alkylester)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid C1-5-alkylester)-1-yl]-propoxy, -OCH2-(CH2)m-NHSO2R", -OCH2-CH(OH)-CH2-NHS02R'^ -OCH2-(CH2)n,-NHCOR'\ -0CH2-CH(0H)-CH2-NHC0R'^\ -NR'^'R''^ -NHCO-R'\or-SOgNHR'^'; R®^ represents hydrogen, C1-3-alkyl, 2-hydroxyethyl, 2-hydroxy-1-hydroxynnethyl-ethyl, 2,3-dihydroxypropyl, carboxymethyl, (C1-5-alkylcarboxy)methyl, 2-carboxyethyl, 2-(C1-5-alkylcarboxy)ethyl, or 2-aminoethyl; R®^ represents hydrogen, methyl, or ethyl; R" represents Ci.3-alkyl, methylamino, ethylamino, or dimethylamino; R^* represents hydroxy-Ci.2-alkyl, or R^^R®'^N-Ci-2-alkyl; R^^ and R^^ independently represent hydrogen, or methyl; k represents the integer 1, 2, or 3; m represents the integer 1 or 2; n represents 0, 1, or 2; and R^ represents hydrogen, C1-1-alkyl, or halogen; and salts thereof. wherein the asterisk indicates the bond that is linked to the pyridine group of formula (I); and salts thereof. 4. Compounds of formula (I) according to any one of claims 1 to 3 wherein R1 represents methyl or ethyl; and salts thereof. 5. Compounds of formula (I) according to any one of claims 1 to 4 wherein R2 represents C1-3-alkyl; and salts thereof. 6. Compounds of formula (I) according to any one of claims 1 to 5 wherein R3 represents C1-4-aikyl; and salts thereof. 7. Compounds of formula (I) according to any one of claims 1 to 6 wherein R4 represents hydrogen; R5 represents methyl, or ethyl; and R7 represents methyl; and salts thereof. 8. Compounds of formula (I) according to any one of claims 1 to 7 wherein R^ represents hydrogen, 2,3-dihydroxypropyl, di-(hydroxy-C1-4-alkyl)-C1-4-alkyl, -CH2-(CH2)k-NHS02R^^ -(CH2)nCH(OH)-CH2-NHS02R'', -CH2-(CH2)K-NHCOR'^', ^(CH2)nCH(OH)-CH2-NHCOR'^', -CH2-(CH2)n-CONR'^' R'^^ 1 -(3-carboxy-azetidinyl)-2-acetyl, 1 -(2-carboxy-pyrrolidinyl)-2- acetyl, 1-(3-carboxy-pyrrolidinyl)-2-acetyl, 1-(3-carboxy-azetidinyl)-3-propionyl, 1-(2- carboxy-pyrrolidinyl)-3-propionyl, 1 -(3-carboxy-pyrrolidinyl)-3-propionyl, -(CH2)nCH(0H)- CH2■NR'^^R'^^ hydroxy, C1-4-alkoxy, hydroxy-C2-5-alkoxy, di-(hydroxy-C1-4-alkyl)-C1-4-alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-methoxy-propoxy, -OCH2-(CH2)m-NR°^R^^ 2- [(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(azetidine-3-carboxylic acid C1-5-alkylester)-1- yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid Ci 5-alkylester)-1-yl]-ethoxy, -OCH2-CH(OH)-CH2-NR^^R^^ 3-[(a2etidine-3-carboxylic acid)- 1-yl]-2-hydroxypropoxy, 3-[(azetidine-3-carboxylic acid C1-5-alkylester)-1-yl]-2- hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3- [(pyrrolidine-3-carboxylic acid Ci.5-alkylester)-1 -yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2- carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid C1-5-alkylester)-!- yl]-propoxy, -OCH2-(CH2),„-NHS02R'', -OCH2-CH(OH)-CH2-NHS02R'', 'OCH2-(CH2),^- NHCOR^', -OCH2-CH(OH)-CH2-NHCOR'\ or -NR'^R''; and salts thereof. 9. Compounds of formula (I) according to any one of claims 1 to 7 wherein R° represents -CH2-(CH2)n-CONR*'^R^', 2,3-dihydroxy-propoxy, or -0CH2-CH(0H)-CH2-NHC0R'"'; and salts thereof. 10. Compounds of formula (I) according to any one of claims 1 to 7 wherein R® represents 2,3-dihydroxy-propoxy, or -OCH2-CH(OH)-CH2-NHCOR^''; and salts thereof. 11. A compound according to claim 1 selected from the group consisting of: (R)-3-{4-[5-(2-diethylamino-6-ethyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-propane-1,2-diol; (S)-3-{4-[5-(2-diethylamino-6-ethyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-propane-1,2-diol; (R)-3-{4-[5-(2-diethylamino-6-methyl~pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-propane-1,2-diol; (S)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-propane-1,2-dioi; (R)-3-(2-ethyl-4-{5-[2-(ethyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6- nnethyl-phenoxy)-propane-1,2-diol; (S)-3-(2-ethyl-4-{5-[2-(ethyl-methyl-amino)-6-nnethyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yi}-6- methyl-phenoxy)-propane-1,2-diol; (R)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadia20l-3-yl]-2,6-dimethyl- phenoxy}-propane-1,2-diol; (S)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl- phenoxy}-propane-1,2-diol; N-((R)-3-{4-[5-(2-dimethylamino-6-0thyl-pyridin-4-yi)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(2-dimethylamino-6-ethyl-pyridin-4-yl)-[1,2,4]oxadia2ol-3-yl]-2-ethyl-6-methyl- phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; (R)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-propane-1,2-diol; (S)-3-{4-[5-(2-diethylamino-6-niethyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-propane-1,2-diol; (R)-3-(4-{5-[2-(ethyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadia2ol-3-yl}-2,6- dimethyl-phenoxy)-propane-1,2-diol; (S)-3-(4-{5-[2-(ethyl-methyl-annino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-2,6- dimethyl-phenoxy)-propane-1,2-diol; (S)-3-(4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-2,6- dimethyl-phenoxy)-propane-1,2-diol; N-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((R)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; and (S)-3-(2-ethyl-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}- 6-methyl-phenoxy)-propane-1,2-diol; and salts thereof. 12. A compound according to claim 1 selected from the group consisting of: 4-{5-[2'(isopropyl-methy(-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadia2ol-3-yl}-2,6-dimethyl-phenol; 3-[3-(2-ethyl"4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenyl)-propionylamino]-propionic acid; N-[(R)-3-(2-ethyl-4-{5-[2-(ethyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; N-[(S)-3-(2-ethyl-4-{5-[2-(ethyl-methyl-amino)-6-methyl-pyridin-4-yI]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; N-[(R)-3-(2-ethyl-4-{3-[2-(ethyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-5-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; N-[(S)-3-(2-ethyl-4-{3-[2-(ethyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-5-yi}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; 1-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-azetidine-3-carboxylicacid; 1-(2-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethyl)-pyrrolidine-3-(S)-carboxylic acid; 1-(2-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethyl)-pyrrolidine-3-(R)-carboxylic acid; (3-{4-[5-(2-diethylamino-6-methyl-pyridin-4'yl)-[1,2,4]oxadia2ol-3-yl]-2-ethyl-6-methyl-phenyl}-propionylamino)-acetic acid; 3-(3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionylamino)-propionic acid; (R).3.{4-[3-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadia2oi-5-yl]-2-ethyi-6-methyl-phenoxy}-propane-1,2-diol; N-((R)-3-{4-[3-(2-diethyiamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[3-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,3,4]oxadiazol-2-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,3,4]thiadiazol-2-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(2--diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-methyl-6-propyl-phenoxy}-2-hydroxy'propyl)-2-hydroxy-acetamide; (R)-3-{2-chloro-4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol; (S)-3"{2-chloro-4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol"3-yl]-6-methyl-phenoxy}-propane-1,2-diol; N-({R)-3-{2-chloro-4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetannide; N-((S)-3-{2-chioro-4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadia2ol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetannide; {4-[3-(4-amino-3-chloro-5-methyl-phenyl)-[1,2,4]oxadiazol-5-yl]-6-methyl-pyridin-2-yl}-diethyl-amine; (R)-3-{2-chloro-4-[5-(2-diethylamino-6-metliyl-pyridin"4-yl)-[1,2,4]oxadiazol-3-yl]-6-methoxy-phenoxy}-propane-1,2-diol; (S)-3-{2-chloro-4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadia2ol-3-yl]-6-methoxy-phenoxy}-propane-1,2-diol; (S)-1-amino-3-{2-chloro-4-[5-(2-diethylannino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methoxy-phenoxy}-propan-2-ol; N-((R)-3-{2-chloro-4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methoxy-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetannide; N-((S)-3-{2-chloro-4-[5-(2-diethylannino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methoxy-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; (S)-3-{2,6-dichloro-4-[5-(2-diethylamino-6-methyl-pyridln-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol; (R)-3-{2,6-dichloro-4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol; N-[(R)-3-(2-ethyl-4-{5-[2-(isopropyl-methyl-amino)-6-nnethyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; N-[(S)-3-(2-ethyl-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; 3-(2-ethyl-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-y(}-6-methyl-phenyl)-N-(2-hydroxy-ethyl)-propionamide; 2-hydroxy-N-[(S)-2-hydroxy-3-(4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-2-methyl-6-propyl-phenoxy)-propyl]-acetamide; (R)-3-(2-chloro-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-propane-1,2-diol; (S)-3-(2-chloro-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-propane-1,2-diol; N-[(R)-3-(2-chloro-4-{5-[2-(isopropyl-nnethyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; N-[(S)-3-(2-chloro-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; (R)-3-(2-chloro-4-{5-[2-(isopropyl-methyl-annino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methoxy-phenoxy)-propane-1,2-diol; (S)-3-{2-chloro-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methoxy-phenoxy)-propane-1,2-diol; (R)-1-amino-3"(2-chloro-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadtazol-3-yl}-6-methoxy-phenoxy)-propan-2-ol; (S)-1-amino-3-(2-chloro-4-{5-[2-(isopropyl-methyl-amino)-6-metliyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methoxy-phenoxy)-propan-2-ol; N-[(R)-3-(2-chloro-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}~6-methoxy-phenoxy)-2-hydroxy-propyl]-2-tiydroxy-acetamide; N-[(S)-3-(2-chloro-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-metlioxy-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; (R)-3-(4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-3-methoxy-phenoxy)-propane-1,2-diol; (S)-3-(4-{5-[2-(isopropyl-methyl-amino)-6-methyi-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-3-methoxy-phenoxy)-propane-1,2-diol; 2-hydroxy-N-[(R)-2-hydroxy-3-(4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,?,4]oxadia2ol-3-yl}-3-methoxy-phenoxy)-propyl]-acetamide; 2-hydroxy-N-[(S)-2-hydroxy-3-(4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-3-methoxy-phenoxy)-propyl]-acetamide; (R)-3-(2-ethyl-4-{3-[2-(isopropyl-methyl-amino)-6'methyl-pyridin-4-yl]-[1,2,4]oxadia2ol-5-yl}-6-methyl-phenoxy)-propane-1,2-diol; N-[(S)-3-(2-ethyl-4-{3-[2-(isopropyl-methyl-annino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-5-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamidG; N-[(S)-3-(2-ethyl-4-{5-[2-(isopropyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,3,4]oxadiazol-2-yl}-6-metiiyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; N-((R)-3-{2-ethyl-6-methyl-4-[5-(2-methyl-6-pyrrolidin-1-yl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{2-ethyl-6-methyl-4-[5-(2-methyl-6-pyrrolidin-1-yl-pyridin-4-yl)-[1,2,4]oxadia20l-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(2-dimethylamino-6-ethyl-pyridin-4'yl)-[1,2,4]oxadia2ol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; (S)-3-{4-[5-(2-diethylamino-6-ethyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol; (R)-3-{2-ethyl-4-[5-(2-isopropylannino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6~ methyl-phenoxy}-propane-1,2-diol; (S)-3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol; N-((R)-3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadia2ol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-[(R)-3-(2-ethyl-4-{5-[2-ethyl-6-(ethyl-methyl-amino)-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; N-[(S)-3-(2-ethyl-4-{5-[2-ethyl-6-(ethyl-methyl-amino)-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; N-[(S)-3-(2-ethyl-4-{5-[2-(isobutyl-methyl-amino)-6-methyl-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; (S)-3-(4-{5-[2-chloro-6-(isopropyl-methyl-amino)-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-2,6-dimethyl-phenoxy)-propane-1,2-diol; (R)-3-(4-{5-[2-chloro-6-(isopropyl-methyl-amino)-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-2,6-dimethyl-phenoxy)-propane-1,2-diol; (S)-N-[3-(4-{5-[2-chlorO"6-(isopropyl-methyl-amino)-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-2,6-dimethyl-phenoxy)-2-hydroxy-propyl)-2-hydroxy-acetamide; and (R)-N-[3-(4-{5-[2-chloro-6-(isopropyl-methyl-amino)-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-2,6-dimethyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide; and salts thereof. 13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 14. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 13, for use as a medicament. 15. Use of a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the prevention or treatment of diseases or disorders associated with an activated immune system. 16. The use according to claim 15 for the prevention or treatment of diseases or disorders selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; solid cancers and tumor metastasis.